SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-055288
Filing Date
2024-06-24
Accepted
2024-06-24 17:15:10
Documents
15
Period of Report
2024-03-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea0208383-8ka1_abvcbio.htm   iXBRL 8-K/A 28051
2 AMENDMENT TO THE DEFINITIVE LICENSE AGREEMENT BETWEEN THE COMPANY AND FORSEECON ea020838301ex10-1_abvcbio.htm EX-10.1 10426
3 AMENDMENT TO THE DEFINITIVE LICENSE AGREEMENT BETWEEN BIOFIRST CORPORATION AND F ea020838301ex10-2_abvcbio.htm EX-10.2 10503
  Complete submission text file 0001213900-24-055288.txt   228095

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20240326.xsd EX-101.SCH 3021
5 XBRL LABEL FILE abvc-20240326_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE abvc-20240326_pre.xml EX-101.PRE 22363
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0208383-8ka1_abvcbio_htm.xml XML 3698
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

IRS No.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40700 | Film No.: 241065298
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)